RBC Raises Ligand Pharmaceuticals Price Target to $357 From $345
RBC Capital Markets maintained its Outperform rating. The update followed Ligand's third-quarter 2026 results and increase to its 2026 adjusted EPS guidance.
RBC Capital Markets maintained its Outperform rating. The update followed Ligand's third-quarter 2026 results and increase to its 2026 adjusted EPS guidance.